Seelos Therapeutics has filed a patent for methods and compositions to treat neurodegenerative diseases using adeno-associated viral vectors encoding peptides inhibiting a-synuclein aggregation. The composition includes a viral vector with a coding sequence for a specific peptide. GlobalData’s report on Seelos Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Seelos Therapeutics, Inc. - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Seelos Therapeutics, Recombinant AAV gene therapy was a key innovation area identified from patents. Seelos Therapeutics's grant share as of January 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.

A recently filed patent (Publication Number: US20240025953A1) discloses a composition involving a viral vector containing a coding sequence that encodes a peptide with a specific amino acid sequence. The peptide, ranging from 9 to 45 amino acids in length, is designed to inhibit a-synuclein aggregation by binding to specific residues of a-synuclein. The viral vector specified in the patent is an AAV vector, with various serotypes such as AAV1, AAV2, AAV3, and others being mentioned as potential options for delivery.

Furthermore, the patent outlines methods for treating neurodegenerative diseases, including Alzheimer's disease and synucleinopathies, by administering the disclosed composition to subjects in need. The methods aim to reduce a-synuclein aggregation in individuals with neurodegenerative diseases, particularly targeting conditions like Lewy body disorder, Parkinson's disease, and multiple system atrophy. Additionally, the patent describes a method for expressing the inhibitory peptide in mammalian cells by introducing the viral vector, as well as a kit containing the composition and instructions for the treatment method outlined in the patent.

To know more about GlobalData’s detailed insights on Seelos Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies